News » DM Zone news, England » First 11 Category H products named
February 5th 2026
The first 11 products to move from Category C to the new Category H in March have been named.
These are given below with the February Drug Tariff (Cat C) price (and price basis) given for comparison with the March prices when these become available.
The 11 products are:
|
Product |
Feb 2026 Cat C price |
Cat C brand basis |
|
Cinchocaine 5mg / Hydrocortisone 5mg suppositories |
£5.08 |
Proctosedyl |
|
Doxazosin 4mg modified-release tablets |
£5.00 |
Cardura XL |
|
Etodolac 600mg modified-release tablets |
£15.50 |
Lodine SR |
|
Isosorbide mononitrate 25mg modified-release capsules |
£4.22 |
Elantan LA25 |
|
Nicotine 4mg medicated chewing gum sugar free |
£13.57 |
Nicotinell |
|
Omeprazole 10mg dispersible gastro-resistant tablets |
£9.30 |
Losec MUPS |
|
Omeprazole 20mg dispersible gastro-resistant tablets |
£13.92 |
Losec MUPS |
|
Omeprazole 40mg dispersible gastro-resistant tablets |
£6.96 |
Losec MUPS |
|
Pseudoephedrine hydrochloride 60mg tablets |
£3.00 |
Sudafed Decongestant |
|
Ursodeoxycholic acid 500mg tablets |
£80.00 |
Ursofalk |
|
Verapamil 120mg modified-release tablets |
£7.71 |
Half - Securon SR |
According to a briefing by Community Pharmacy England, which was involved in the negotiations relating to the new Category H, the Drug Tariff prices for Category H drugs will be updated quarterly in the following months: March, June, September and December.
This means that DHSC will be using lagged data to set Category H reimbursement prices and states that the March 2026 Drug Tariff will be based on market data obtained by DHSC between September – November 2025.
Community Pharmacy England is concerned that the new price-setting arrangements will introduce price volatility and potentially draw more drugs into the price concession process, cause more supply disruptions and increase the risk of dispensing certain branded products at a loss. DHSC maintains that if a pharmacy is unable to purchase a particular Part VIII drug at or below the published Drug Tariff price, an application can be made for a price concession.
